News
Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...
15h
GlobalData on MSNNeuron23 doses first subject in Phase II trial of NEU-411 for Parkinson’sApproximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.
Researchers have uncovered another piece of the Parkinson’s disease puzzle, identifying that particular immune cells are ...
8d
News-Medical.Net on MSNBlack tea helps in one Parkinson’s type, but soda and pesticides worsen anotherA large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...
BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced ...
7d
News-Medical.Net on MSNEqual access, unequal impact: Parkinson’s hits minorities harder in the UKResearchers in East London found that South Asian and Black Parkinson’s disease patients experience more severe motor and ...
Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...
When 64-year-old MBK Nair first noticed a subtle tremor in his right hand in 2020, he brushed it off as fatigue or muscle weakness, assuming that could be a sig ...
Differences in the chemicals people's bodies produce - which some people can even smell - may help detect the disease much ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results